28
Participants
Start Date
April 20, 2017
Primary Completion Date
December 1, 2019
Study Completion Date
December 1, 2019
B-701
B-701 (vofatamab) is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
Pembrolizumab
Pembrolizumab is a humanized antibody used in cancer immunotherapy. Pembrolizumab targets and blocks a protein called PD-1 on the surface of certain immune cells called T-cells. Blocking PD-1 triggers the T-cells to find and kill cancer cells.
Research Site, Brussels
Research Site, Budapest
Research Site, Chisinau
Research Team, Copenhagen
Research Site, Leuven
Research Team, Yvoir
Research Site, Belgrade
Research Site, Belgrade
Research Site, Seongnam-si
Research Site, Niš
Research Site, Philadelphia
Research Site, Milan
Research Site, Milan
Research Site, Dijon
Research Site, Kamenitz
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Bordeaux
Research Site, Kragujevac
Research Site, Kassel
Research Site, Germantown
Research Site, Louisville
Research Site, Cleveland
Research Site, Fort Wayne
Research Site, Münster
Research Site, Dnipro
Research Site, Frankfurt
Research Site, Gwangju
Washington University School of Medicine, St Louis
Research Site, Heidelberg
Research Site, Uppsala
Research Site, Houston
Research Site, Munich
Research Site, Greenbrae
Research Site, Moscow
Research Site, Saint Petersburg
Research Team, Ufa
Research Site, Dresden
Research Site, Utrecht
Research Site, Katowice
Research Site, Warsaw
Research Site, Warsaw
Research Site, Wieliszew
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Barcelona
Research Site, Ankara
Research Site, Antalya
Research Site, Kyiv
Lead Sponsor
Rainier Therapeutics
INDUSTRY